Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH
and OCT Clinical GmbH

Xlife Sciences AG / Key word(s): Alliance/Merger
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH
and OCT Clinical GmbH

27.05.2024 / 07:00 CET/CEST

---------------------------------------------------------------------------

Zurich, 27th of May 2024: Xlife Sciences AG announces the merger of its
portfolio company, palleos healthcare GmbH, with OCT Clinical GmbH. This
merger represents a significant milestone in establishing a leading company
in the field of clinical research.

palleos healthcare, a Germany-based contract research organization (CRO)
focused on oncology, and OCT Clinical, a full-service CRO, have officially
merged following the signing of the contract on May 24, 2024.

The merger combines the unique strengths and expertise of both companies,
positioning them to offer comprehensive end-to-end services and solutions
globally. palleos healthcare, with its primary activities in Western and
Central Europe (Germany, Austria, and Switzerland), and OCT Clinical, which
focuses on Eastern Europe (Poland, Hungary, Baltic States, Ukraine, and
Bulgaria), will now jointly recruit patients in a region with a total
population of over 300 million people. Henceforth, the combined company will
operate under the brand name palleos healthcare.

Dr Philip Räth, Managing Director of palleos healthcare, comments on the
merger: "I'm certain that the merger will not just double the expertise of
both companies, but square it, thanks to synergistic effects. While OCT
Clinical previously just concentrated on the Eastern European market and
palleos healthcare on the Central one, together we now cover the entire
region, from product development and pre-clinical consulting to regulatory
affairs and clinical trials."

Dmitry Sharov, CEO of OCT Clinical, adds: "OCT Clinical is proud to join
forces with palleos healthcare, as it has an excellent reputation in the
industry it serves. Now we can offer tailored solutions to our clients to
meet their diverse clinical research needs and accelerate the time of
bringing their products to market."

Oliver R. Baumann, CEO of Xlife Sciences, expresses his enthusiasm: "We are
excited about the merger of palleos healthcare and OCT Clinical to offer
better CRO solutions for global markets. As a strategic partner and
shareholder of palleos healthcare, Xlife Sciences sees great potential in
this union to increase reach and expand service capacities. This merger
promises to deliver top-notch solutions for clinical research and advance
global healthcare."

Notably, according to the U.S. Food and Drug Administration (FDA), out of
the 55 novel drugs approved in 2023, 42 underwent clinical trials in Europe,
including Germany, Georgia, Poland, Hungary, Bulgaria, Romania, Czech
Republic, Serbia, Ukraine, and Latvia. Additionally, according to an FDA
report, a total of seven Central and Eastern European countries were among
the top ten in terms of the number of clinical trial participants,
underscoring the strategic importance of this merger for pharmaceutical
companies seeking efficient solutions for patient recruitment and successful
study outcomes.

This strategic partnership underscores Xlife Sciences commitment to bridging
the gap between innovative research and practical healthcare applications,
ultimately improving the global landscape of clinical research.

Financial calendar

     Annual Shareholders Meeting 2024    28 June 2024
     Half-Year Report 2024               19 September 2024

Kontakt;
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis
Fink, dennis.fink@xlifesciences.ch
Contact information palleos healthcare GmbH: pr@palleos.com
Contact information OCT Clinical GmbH: pr@oct-clinicaltrials.com

Xlife Sciences AG,
Talacker 35,
8001 Zurich,
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on
the value development and commercialization of promising research projects
from universities and other research institutions in the life sciences
sector, with the aim of providing solutions for high unmet medical needs and
a better quality of life. The goal is to bridge research and development to
healthcare markets. Xlife Sciences takes carefully selected projects in the
four areas of technological platforms, biotechnology/ therapies, medical
technology, and artificial intelligence/digital health to the next stage of
development, and participates in their subsequent performance. For more
information, visit www.xlifesciences.ch

About palleos healthcare GmbH

palleos healthcare is a full-service contract research organization (CRO)
focused on the development of healthcare products and based in Central
Europe. Over 10,000 patients at 300 sites have been treated in various
studies and indications, with the results of these studies published in
high-ranking journals and presented at conferences (e.g., ASCO Annual
Meeting). As a certified partner with highly regarded players in the digital
life sciences sector (e.g. Veeva and Medidata), palleos healthcare also
offers cloud-based services (data management platform and decentralized
clinical trials) for the development of clinical drugs and medical devices.
For more information, visit www.palleos.com

About OCT Clinical

OCT Clinical is a full-service contract research organization and a leader
in the Eastern European market. The company's portfolio already includes
more than 360 I-IV and BE clinical trials in the field of Oncology,
Infectious Diseases, GI, Rheumatology, and other therapeutic areas. For more
information, visit www.oct-clinicaltrials.com

Disclaimer

Some of the information contained in this media release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ
materially from those in the forward-looking statements as a result of
various factors. Xlife Sciences undertakes no obligation to publicly update
or revise any forward-looking statements.


---------------------------------------------------------------------------

End of Media Release

---------------------------------------------------------------------------

   Language:       English
   Company:        Xlife Sciences AG
                   Talacker 35
                   8001 Zürich
                   Switzerland
   Phone:          +41 44 385 84 60
   E-mail:         info@xlifesciences.ch
   Internet:       www.xlifesciences.ch
   ISIN:           CH0461929603
   Valor:          A2PK6Z
   Listed:         SIX Swiss Exchange
   EQS News ID:    1911105

End of News EQS News Service
---------------------------------------------------------------------------

1911105 27.05.2024 CET/CEST